Clinical Trials Browser

Observational × Hypersensitivity × Plasma cell × Clear all

NCT05635266 2024-05-07

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Classical hematologyGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cell

red meat allergy, Alopecia Areata, Alzheimer Disease, Amyloidosis, Anemia, Sickle Cell, Arthritis, Asthma, Autistic Disorder, Behcet Syndrome, Celiac Disease, Colitis, Ulcerative, Crohn Disease, Cystic Fibrosis, Dermatitis, Atopic, Diabetes Mellitus, Epilepsies, Myoclonic, Fibrosis, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hypersensitivity, Kidney Diseases, Leukemia, Lupus Erythematosus, Systemic, Lymphoma, Macular Degeneration, Multiple Sclerosis, Myasthenia Gravis, Neoplasms, Parkinson Disease, Pemphigus, Psoriasis, Schizophrenia, Spondylitis, Ankylosing, Thyroid Diseases, Vasculitis, Vitiligo, beta-Thalassemia, Hidradenitis Suppurativa, Hepatitis, Autoimmune, Stroke, Pulmonary Disease, Chronic Obstructive, Scleroderma, Diffuse

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Completed

1,149 enrolled

GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02921802 2022-06-14

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Completed

4,626 enrolled

Classical hematologyMyeloidOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myelodysplastic Syndromes, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT02922543 2022-06-14

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Completed

361 enrolled

Classical hematologyOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis